Challenges to the surveillance of meningococcal disease in an era of declining incidence in Montreal, Quebec.
Ratnayake, Ruwan ; Allard, Robert
Invasive meningococcal disease (IMD) is a major cause of epidemic
meningitis, and may be fulminant or lethal. (1) In Quebec, the case
fatality ratio from 1997 to 2011 was 15% for serogroup C and 5.7% for
serogroup B. (2) Long-term sequelae, including loss of limbs, hearing
and renal problems occur in 3-15% of cases. (3) Decreases in the
incidence of serogroup C disease were observed following serogroup C
outbreaks in Quebec and associated mass vaccination campaigns among
persons 6 months to 20 years of age in 1993 and 2001. (4,5) From 2001,
the National Advisory Committee on Immunization (NACI) recommended
routine and catch-up vaccination using the monovalent serogroup C
vaccine for infants, children aged one to four years, adolescents and
young adults up to 20 years of age. (6) In Quebec since 2002, one dose
of serogroup C vaccine is administered to children at 12 months of age.
Accordingly, vaccination coverage by 24 months is 96%. (7) In parallel
with these provincial and national estimations, the incidence in
Montreal decreased by over 50%, from 1.6 to 0.5 cases per 100,000 in
1995 and 2008, respectively (Figure 1).
In Montreal, physicians and laboratories are mandated to promptly
report to the local public health department by phone or fax probable
and laboratory-confirmed cases based on a standardized case definition.
(8) This enables the department to conduct epidemiological
investigation, post-exposure prophylaxis (PEP), vaccination for
household contacts of a case infected by a vaccine-preventable
serogroup, and surveillance to observe changes in incidence and
serogroup predominance. A previous evaluation of IMD surveillance in
Montreal from 1993-1995 found that the sensitivity was high (94.8%) and
the timeliness was reasonable (85.3% reported within six days). (9) In
an era of declining incidence, we were concerned about complete and
timely reporting. We evaluated the sensitivity and timeliness of
reporting and the capacity to statistically detect clusters; this could
facilitate early identification of common characteristics or venues
amenable to intervention. To produce results that are comparable with
the previous sensitivity and timeliness evaluation conducted April 1,
1993 to March 31, 1995, we conducted these analyses for the period April
1, 1995 to December 31, 2008. We used a longer period to evaluate the
statistical detection of clusters, January 1, 1992 to December 31, 2008,
to include a period of high incidence in the early 1990s.
METHODS
[FIGURE 1 OMITTED]
Case definitions
The case definitions used are those established by the Ministere de
la Sante et des Services sociaux de Quebec and correspond with those
recommended by the Public Health Agency of Canada: (8,10) A confirmed
case includes:
* Clinical evidence of invasive disease with laboratory
confirmation of infection through isolation of N. meningitidis from a
normally sterile site (blood, cerebrospinal fluid, joint, pleural or
pericardial fluid)
A probable case includes:
* Clinical evidence of invasive disease including meningitis and/or
septicaemia with purpura fulminans or petechiae, OR
* Clinical evidence of invasive disease AND detection of N.
meningitidis antigen in the cerebrospinal fluid.
To be counted as a case in Montreal, patients must have been
residents of and must have become ill in Montreal or have become ill
elsewhere and have been transferred to Montreal.
To measure sensitivity, we compared data on confirmed and probable
IMD cases among Montreal residents between April 1, 1995 and December
31, 2008 using two independent data sources: the reportable disease
database (RDD) and the provincial hospitalization database (Maintenance
et exploitation des donnees pour l'etude de la clientele
hospitaliere or MED-ECHO). We extracted hospitalizations using ICD-9
(036.0-036.9; used 1995-2005) and ICD-10 (A39.0-39.9, used 2006-2008)
codes associated with IMD. This assumed that all IMD cases are
hospitalized. The sensitivity of case reporting was calculated using the
cases reported to the RDD (R) divided by the total estimated cases by a
capture-recapture calculation (N). (11) As MED-ECHO records are
non-nominal, the datasets were linked manually by age, sex and a
three-day window between the dates of reporting and dates of admission.
For the unmatched MED-ECHO entries, an epidemiologist reviewed hospital
and laboratory records against the case definition.
The timeliness for reporting by physicians and laboratories was
calculated as the difference in days between the date of specimen
collection (signifying physician contact) and the date of reporting. A
7-day limit was deemed to be a realistic period during which PEP can be
administered within the 14-day period in which it is most effective,
accounting for delays in reaching household contacts. (12)
The space-time scan statistic (STSS) was used to detect cluster
signals for January 1, 1992 to December 31, 2008, as implemented by
SaTScan[TM] version 9.0 [http://www.satscan.org/]. SaTScan examines the
relative risk (RR) or ratio of observed numbers of cases inside and
outside a cluster given the population density. Cases were assigned a
time-code (date of specimen collection), geo-code (the Canada Post
forward sortation area [FSA] of residence as a proxy for exposure to
household contacts) and population at risk (census population by FSA). A
Poisson distribution of numbers of cases per FSA was assumed. Likelihood
ratio statistics and Monte-Carlo simulations produced a P-value for each
cluster indicating its statistical significance of occurring not due to
chance (p<0.05). A cluster was defined as two or more serogroup B or
C cases bound too tightly in time ([less than or equal to] 40 days
between the date of specimen collection for the first and last case, or
four times the longest incubation period) and geographic location
(cluster area included <50% of the Montreal population) to be
produced by chance. Cluster signals were tested retrospectively. When a
cluster was detected retrospectively, we applied repeated prospective
scans. Prospective scans simulated the addition of cases over time in
order to evaluate the generation of early warning signals resulting from
the addition of each successive case. The delay between the first early
warning signal and the date of each subsequent case was calculated to
estimate how early the cluster was detected. These results were compared
with observations of clustering found in case files.
As a program evaluation, this protocol did not require ethical
review.
RESULTS
The date of specimen collection was present for 168 (91.3%) of the
184 cases retrieved from the RDD (R) for 1995 to 2008. There were 147
hospitalizations retrieved from MED-ECHO (S) (Table 1). A total of 133
cases were found in both datasets (C), 51 in RDD only ([N.sub.1]) and 14
in MED-ECHO only. Investigation of the 14 unmatched hospitalizations
found 8 true cases ([N.sub.2]) and 6 false-positive cases. Three of the
eight true cases met the confirmed case definition and were supported by
laboratory confirmation, and five of the eight could not be retrieved
without a date of birth and were considered confirmed without laboratory
confirmation. Of the six false-positive hospitalizations, three of the
six were unrelated meningitis (not N. meningitidis), two of the six had
a change in discharge diagnosis and one of the six had a coding error.
Therefore, we adjusted the number of MED-ECHO hospitalizations from 147
to 141 (147 minus 6 false-positive cases). Capture-recapture estimated
195 total cases. The sensitivity was 94.3% [95% CI 90.5-97].
Of the 184 reported cases, 100 (54.3%) and 168 (91.3%) were
reported by physicians and laboratories, respectively. Of the 168 cases
with a date of specimen collection, 87 (51.8%) were reported within
seven days by physicians (range 0 to 13 days) and 115 (68.5%) were
reported within seven days by laboratories (range 0 to 39 days) (Figure
2). Overall, 155 (92.3%) cases were reported within seven days by the
first reporting source. Physicians tended to report a higher proportion
of cases within days zero to two (40.5%), which is reflected in two
thirds of all cases being reported by the first reporter by day two
(66.7%). From days three to seven, laboratories reported a consistently
higher proportion of cases (50.6% to 68.5%) compared to physicians
(45.8% to 51.8%).
For the 206 cases from 1992 to 2008, 2 of the 11 clusters detected
were statistically significant. Four clustered serogroup C cases were
reported between December 9, 1993 and January 5, 1994 (RR=81.1,
p<0.04). Although two deaths occurred in a short time span, the case
files did not indicate that this cluster was detected or investigated in
real time and no microbiological subtyping information was available to
explore its plausibility. Prospective detection signalled the cluster
when the second case was added on December 22 and then again with each
successive case. The detection time was reduced by 6 to 14 days. Five
serogroup B cases were reported between September 21 and October 25,
1995 (RR=54.9, p<0.02). An overlapping cluster of five serogroup B
cases with matching electrophoretic profiles (ET-5) between September 23
and October 20, 1995 was manually detected in 1995 and investigated;
three of the five cases frequented raves, and links to a specific bar
were also demonstrated. (13) Prospective detection signalled the cluster
when the second case was added on October 7, and again with each
successive case, reducing detection time by 8-13 days. From the case
files and the published outbreak report, we were unable to identify the
date that the cluster was manually detected.
DISCUSSION
Case-reporting sensitivity remained high with 94.3% of cases
reported to the surveillance system, similar to the 1993-1995
capture-recapture estimate for Montreal (94.8%). (9) The overall
timeliness of reporting was inadequate. The proportion (54%) of
physician reports was low; 46% of cases were dependent on
time-insensitive laboratory reporting, which tended to increase slowly
after the first two days. To compare,
physicians reported 70% of cases in Montreal in 1993-1995.9 The
proportion of physicians reporting cases compares negatively to that of
a comparably sized population in Thames Valley, UK (90%). (14) This may
affect the ability of the public health department to administer PEP and
vaccination to contacts in the 14-day window. A total of 92.3% of cases
were notified by physicians or laboratories within seven days, meaning
that in theory, 13 cases were not notified in time to conduct thorough
contact tracing and offer PEP when indicated. Correcting these avoidable
delays may prevent such secondary cases as have been recently documented
in the UK and the US. (15,16)
Without specific mention of IMD, a previous survey on the knowledge
of notifiable diseases reporting among emergency physicians in Canada
showed substantial barriers concerning knowledge on which diseases to
report to the public health department and the time and effort required
to report. (17) However, as a severe disease that affects children which
can be notified on a clinical basis before any laboratory confirmation,
it follows that physician reporting is likely to be more assured for IMD
as compared to other reportable diseases. (18) In this case, reporting
appears to have shifted to laboratories. Therefore, ad-hoc reminders to
physicians and the posting of reportable disease lists and guidelines
for reporting procedures in emergency rooms may be useful. (17) For
laboratories, automated electronic reporting of results using an online
system would be ideal for increasing speed. However, this will require
accommodating the various types of software used in laboratories and
hospitals, which is currently not feasible.
Space-time scan statistics detected cluster signals at the local
level in 1994 and 1995. One cluster signal was shown to have evidence of
being microbiologically-linked through identical microbiological
profiles, and the prospective method identified an emerging outbreak
linked to a risk group ("ravers"). (13) This provided early
warning of a suspected cluster before the serotyping that traditionally
confirms an outbreak after cumulative cases is undertaken. No cluster
signals were generated after 1995. The decreased incidence since 2001
may have lowered the power to detect clustering, thus limiting
usefulness in a low incidence period. As well, the proportion of
fulminant cases to asymptomatic carriers involved in clusters may be
low. Only 4.4% (9/206) cases were found to be clustered. Similarly, only
4.2% of cases were found to be clustered using STSS with molecular
typing in Germany. (19) At the local level, STSS may be more effective
in detecting clusters of high-incidence diseases such as shigellosis as
compared to meningococcal disease. (20)
There are several limitations to this evaluation. The data sources
may not be completely independent because the public health department
and hospitals may exchange information on cases; this may overestimate
the reporting completeness. (21) The under-reporting of the 51 cases
found in the RDD but not listed in MED-ECHO could not be further
investigated due to lack of identifying data in the MED-ECHO dataset,
but may indicate several possibilities: that infection by N.
meningitidis may have been coded as another bacterial or viral cause of
meningitis in MED-ECHO; for fatal cases, that N. meningitidis may not
have been isolated by the time of completion of the discharge form; and
that some fulminant cases may have been reached by public health but not
hospitalized due to rapid recovery or death. (21,22) To fully explore
these possibilities, registries that contain unique identifiers to
perfectly match cases and hospitalizations would be optimal for routine
evaluations, such as that used in Denmark. (23) Second, the true impact
of the reduced physician reporting is dependent on whether physicians
undertook preventive actions such as administering PEP and vaccinating
contacts (who are often family members to whom they have access). Third,
cluster detection sensitivity was decreased by the inability to
incorporate asymptomatic carriers and geographic locators other than
residence where transmission often occurs (i.e., day cares, workplaces).
Our findings suggest that vigilance towards IMD reporting has
shifted from physicians to laboratories in this era of declining
incidence in Montreal. This may be true for other jurisdictions in
Canada. We recommended three improvements for the surveillance system:
1) reminding physicians to report probable and confirmed cases in order
to provide simultaneous reporting by two sources, 2) restating the role
of the public health department in more extensive contact tracing beyond
family members, and 3) in the absence of automatic electronic reporting,
monitoring and increasing the speed of laboratory reporting. When
incidence is high, daily cluster analysis by serogroup may hasten the
detection of outbreaks by one to two weeks, adding to a public health
practitioner's initial "hunch" of an outbreak before
serotyping is available. Such early warning systems require, as does
routine surveillance, complete and timely reporting by clinicians.
Acknowledgements: We thank Jean Gratton and Maryse Lapierre of the
Direction de sante publique for their help with file retrieval, and the
Canadian Field Epidemiology Program and participants of its scientific
writing workshop for their review of the initial report.
Conflict of Interest: None to declare.
REFERENCES
(1.) Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis,
meningococcaemia, and Neisseria meningitidis. Lancet 2007;
369(9580):2196-210.
(2.) Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V,
et al. The changing epidemiology of meningococcal disease in Quebec,
Canada, 1991-2011: Potential implications of emergence of new strains.
PLoS One 2012; 7(11):e50659. doi: 10.1371/journal.pone.0050659.
(3.) Erickson L, De Wals P. Complications and sequelae of
meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis
1998; 26(5):1159-64.
(4.) De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau
J, De Serres G. Impact of a mass immunization campaign against serogroup
C meningococcus in the Province of Quebec, Canada. Bull WHO 1996;
74(4):407-11.
(5.) DeWals P, Deceuninck G, Boulianne N, DeSerres G. Effectiveness
of a mass immunization campaign using serogroup C meningococcal
conjugate vaccine. JAMA 2004; 292(20):2491-94.
(6.) National Advisory Committee on Immunization. An update on the
invasive meningococcal disease and meningococcal vaccine conjugate
recommendations. An Advisory Committee Statement. Can Commun Dis Rep
2009; 35(ACS3): 1-40.
(7.) Boulianne N, Bradet R, Audet D, Ouakki M, Guay M. Enquete sur
la couverture vaccinale des enfants de 1 an et 2 ans au Quebec en 2010.
Quebec, QC: Institut national de sante publique du Quebec. 2011; 98.
Available at: http://www.inspq.qc.ca/pdf/publications/1318_
EnqueteCouvVaccinEnfants 1Et2AnsQc2010.pdf (Accessed March 25, 2013).
(8.) Ministere de la Sante et des Services sociaux de Quebec. Guide
d'intervention: les infections invasives a meningocoque, mise a
jour 2007. Available at: http://publications.msss.gouv.qc.ca/
acrobat/f/documentation/2009/09-27103.pdf (Accessed August 5, 2012).
(9.) Rivest P, Sagot B, Bedard L. Evaluation of the completeness of
reporting of invasive meningococcal disease. Can J Public Health 1999;
90(4):250-52.
(10.) Public Health Agency of Canada. Case definitions for diseases
under national surveillance--2009. Can Commun Dis Rep2009; 35s2.
(11.) Hook EB, Regal RR. Capture-recapture methods in epidemiology:
Methods and limitations. Epidemiol Rev 1995; 17(2):243-64.
(12.) Bilukha OO, Rosenstein N, National Center for Infectious
Diseases, Centers for Disease Control and Prevention. Prevention and
control of meningococcal disease. Recommendations of the Advisory
Committee on Immunization Practices. MMWR Recomm Rep 2005;
54(RR-7):1-21.
(13.) Le Guerrier P, Pilon P, Sauvageau C, Deshaies D.
Spatio-temporal cluster of cases of invasive group B Neisseria
meningitidis infections on the island of Montreal. Can Commun Dis Rep
1997; 23(4):25-28.
(14.) Paranthaman K, Kent L, McCarthy N, Gray SJ. Invasive
meningococcal disease: Completeness and timeliness of reporting of
confirmed cases in Thames Valley, 2006-2007. Public Health 2009;
123(12):805-8.
(15.) Petsas A, Sharma A, Aghadiuno O, Abid M, Paranthaman K. A
secondary case of meningococcal disease in an ambulance worker,
Berkshire, November 2007. Euro Surveill 2008; 13(4):pii=8020.
(16.) Centers for Disease Control and Prevention. Occupational
transmission of Neisseria meningitidis--California, 2009. MMWR 2010; 19;
59(45):1480-83.
(17.) Friedman SM, Sommersall LA, Gardam M, Arenovich T. Suboptimal
reporting of notifiable diseases in Canadian emergency departments: A
survey of emergency physician knowledge, practices, and perceived
barriers. Can Commun Dis Rep 2006; 32(17):187-98.
(18.) Dominguez A, Canela J, Salleras L. Inclusion of laboratory
test results in the surveillance of infectious diseases. Int J Epidemiol
1991; 20(1):290-92.
(19.) Elias J, Harmsen D, Claus H, Hellenbrand W, Frosch M, Vogel
U. Spatiotemporal analysis of invasive meningococcal disease, Germany.
Emerg Infect Dis 2006; 12(11):1689-95.
(20.) Jones RC, Liberatore M, Fernandez JR, Gerber SI. Use of a
prospective spacetime scan statistic to prioritize shigellosis case
investigations in an urban jurisdiction. Public Health Rep 2006;
121(2):133-39.
(21.) Brenner H. Use and limitations of the capture-recapture
method in disease monitoring with two dependent sources. Epidemiology
1995; 6:42-48.
(22.) Ackman DM, Birkhead G, Flynn M. Assessment of surveillance
for meningococcal disease in New York State, 1991. Am J Epidemiol 1996;
144(1):78-82.
(23.) Howitz MF, Samuelsson S, M0lbak K. Declining incidence of
meningococcal disease in Denmark, confirmed by a capture-recapture
analysis for 1994 and 2002. Epidemiol Infect 2008; 136:1088-95.
Received: November 13, 2012
Accepted: April 8, 2013
Ruwan Ratnayake, MHS, [1,2] Robert Allard, MD, MSc, FRCPC [2,3]
Author Affiliations
[1.] Canadian Field Epidemiology Program, Public Health Agency of
Canada, Ottawa, ON
[2.] Public Health Department, Montreal Health and Social Services
Agency, Montreal, QC
[3.] Department of Epidemiology, Biostatistics and Occupational
Health, McGill University, Montreal, QC
Correspondence: Ruwan Ratnayake, Health Unit, International Rescue
Committee, 122 East 42nd Street, New York, NY 10168, Tel : 212-551-0966,
E-mail: ruwan.ratnayake@rescue.org
Table 1. Capture-recapture Estimates and Case Reporting
Sensitivity for IMD Cases, Montreal, April 1, 1995
December 31, 2008
Public Health Registry
Hospitalization Cases Cases Not All
Database Reported Reported Cases
Cases listed 133 8 141
(C) ([N.sub.2]) (S)
Cases not listed 51 3.1 * 54.1
([N.sub.1]) (X)
All cases 184 11.1 195.1 ([dagger])
(R) (N)
* Calculated: X = ([N.sub.2] * [N.sub.1]) / (C) = (8 * 51) /
(133) = 3.07
([dagger]) Calculated: N = C + [N.sub.1] + [N.sub.2] + X = (133) +
(51) + (8) + (3.07) = 195.07
Sensitivity = R / N = 184/195.1 = 94.3% [95% CI = 90.5-97.0]
Figure 2. Cumulative frequency of number of days
to report IMD cases to the public health department, by source,
n=168 cases with date of specimen sampling, Montreal,
April 1, 1995-December 31, 2008
Cumulative frequency of total cases reported (%)
0-1 2 3 4
First reporter 46.4 66.7 78.6 83.3
Physician 31.5 40.5 45.8 48.2
Laboratory 23.2 38.7 50.6 56.5
Cumulative frequency of total cases reported (%)
5 6 7 [greater than
or equal to] 8
First reporter 88.7 90.5 92.3 99.4
Physician 49.4 50.6 51.8 56.0
Laboratory 61.3 65.5 68.5 90.5